Immunocore to present at the 2024 Cantor Global Healthcare Conference
Immunocore Holdings plc (Nasdaq: IMCR), a commercial-stage biotechnology company, has announced its participation in the 2024 Cantor Global Healthcare Conference. The company, which focuses on developing immunomodulating medicines for cancer, infectious diseases, and autoimmune diseases, will be part of a fireside chat on Thursday, September 19, 2024, at 12:45 p.m. EDT.
The presentation will be webcast live and can be accessed through the 'Events & Presentations' section under 'Events' on the 'Investors' page of Immunocore's website. A replay of the presentation will be available for a time after the event.
Immunocore Holdings plc (Nasdaq: IMCR), un'azienda biotecnologica in fase commerciale, ha annunciato la propria partecipazione alla 2024 Cantor Global Healthcare Conference. L'azienda, che si concentra sullo sviluppo di medicinali immunomodulatori per il cancro, le malattie infettive e le malattie autoimmuni, sarà parte di una discussione informale giovedì 19 settembre 2024, alle 12:45 EDT.
La presentazione sarà trasmessa in diretta e sarà accessibile nella sezione 'Eventi e Presentazioni' sotto 'Eventi' nella pagina 'Investitori' del sito web di Immunocore. Una registrazione della presentazione sarà disponibile per un certo periodo dopo l'evento.
Immunocore Holdings plc (Nasdaq: IMCR), una empresa biotecnológica en etapa comercial, ha anunciado su participación en la 2024 Cantor Global Healthcare Conference. La empresa, que se centra en el desarrollo de medicamentos inmunomoduladores para el cáncer, enfermedades infecciosas y enfermedades autoinmunes, formará parte de una charla informal el jueves 19 de septiembre de 2024, a las 12:45 p.m. EDT.
La presentación se transmitirá en vivo y podrá accederse a través de la sección 'Eventos y Presentaciones' en la página de 'Inversores' del sitio web de Immunocore. Una repetición de la presentación estará disponible por un tiempo después del evento.
Immunocore Holdings plc (Nasdaq: IMCR), 상업 단계의 생명공학 회사, 가 2024 Cantor Global Healthcare Conference에 참여한다고 발표했습니다. 암, 감염병 및 자가면역 질환을 위한 면역 조절 약물 개발에 집중하는 이 회사는 2024년 9월 19일 목요일, 오후 12시 45분 EDT에 진행될 화상 상담에 참여하게 됩니다.
이번 발표는 실시간 스트리밍으로 진행되며, Immunocore 웹사이트의 '투자자' 페이지에서 '이벤트' 아래의 '이벤트 및 발표' 섹션을 통해 접근할 수 있습니다. 행사 후 일정 기간 동안 발표 내용의 다시 보기를 제공할 예정입니다.
Immunocore Holdings plc (Nasdaq: IMCR), une entreprise de biotechnologie en phase commerciale, a annoncé sa participation à la 2024 Cantor Global Healthcare Conference. L'entreprise, qui se concentre sur le développement de médicaments immunomodulateurs pour le cancer, les maladies infectieuses et les maladies auto-immunes, fera partie d'une discussion informelle jeudi 19 septembre 2024, à 12h45 EDT.
La présentation sera diffusée en direct et pourra être consultée dans la section 'Événements et Présentations' sous 'Événements' sur la page 'Investisseurs' du site web d'Immunocore. Un enregistrement de la présentation sera disponible pendant un certain temps après l'événement.
Immunocore Holdings plc (Nasdaq: IMCR), ein biotechnologisches Unternehmen in der kommerziellen Phase, hat seine Teilnahme an der 2024 Cantor Global Healthcare Conference bekannt gegeben. Das Unternehmen, das sich auf die Entwicklung von immunmodulatorischen Arzneimitteln für Krebs, Infektionskrankheiten und Autoimmunerkrankungen konzentriert, wird an einem informellen Gespräch am Donnerstag, den 19. September 2024, um 12:45 Uhr EDT teilnehmen.
Die Präsentation wird live übertragen und kann über den Bereich 'Veranstaltungen und Präsentationen' unter 'Veranstaltungen' auf der 'Investoren'-Seite der Immunocore-Website aufgerufen werden. Eine Aufzeichnung der Präsentation wird eine Zeit lang nach der Veranstaltung verfügbar sein.
- None.
- None.
Immunocore to present at the 2024 Cantor Global Healthcare Conference
(OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, 12 September 2024) Immunocore Holdings plc (Nasdaq: IMCR) (“Immunocore” or the “Company”), a commercial-stage biotechnology company pioneering and delivering transformative immunomodulating medicines to radically improve outcomes for patients with cancer, infectious diseases and autoimmune diseases, today announced that management will participate in the 2024 Cantor Global Healthcare Conference.
2024 Cantor Global Healthcare Conference
Fireside Chat: Thursday, September 19, 2024, at 12:45 p.m. EDT
The presentation will be webcast live and can be accessed by visiting ‘Events & Presentations’, under ‘Events’, via the ‘Investors’ section of Immunocore’s website at www.immunocore.com. Following the event, a replay of the presentation will be made available for a limited time.
About Immunocore
Immunocore is a commercial-stage biotechnology company pioneering the development of a novel class of TCR bispecific immunotherapies called ImmTAX – Immune mobilizing monoclonal TCRs Against X disease – designed to treat a broad range of diseases, including cancer, autoimmune, and infectious disease. Leveraging its proprietary, flexible, off-the-shelf ImmTAX platform, Immunocore is developing a deep pipeline in multiple therapeutic areas, including five clinical stage programs in oncology and infectious disease, advanced pre-clinical programs in autoimmune disease and multiple earlier pre-clinical programs. The Company’s most advanced oncology TCR therapeutic, KIMMTRAK has been approved for the treatment of HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma in the United States, European Union, Canada, Australia, and the United Kingdom.
Contact Information
Immunocore
Sébastien Desprez, Head of Communications
T: +44 (0) 7458030732
E: sebastien.desprez@immunocore.com
Follow on Twitter: @Immunocore
Investor Relations
Clayton Robertson, Head of Investor Relations
T: +1 (215) 384-4781
E: ir@immunocore.com
FAQ
When is Immunocore (IMCR) presenting at the 2024 Cantor Global Healthcare Conference?
How can I watch Immunocore's (IMCR) presentation at the 2024 Cantor Global Healthcare Conference?
Will there be a replay available of Immunocore's (IMCR) presentation at the 2024 Cantor Global Healthcare Conference?
What types of diseases does Immunocore (IMCR) focus on in its drug development?
